about
The Utility of Molecular Imaging in Prostate CancerA novel pathogenic classification of cancers.Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of RadioactivityUlipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.High throughput and automatic colony formation assay based on impedance measurement technique.Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissueDNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseasesHitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death.Advances in the recognition and management of hereditary cancer.Massively parallel DNA sequencing from routinely processed cytological smears.Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.Polypharmacology: in silico methods of ligand design and development.Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.Sensitization of K562 Leukemia Cells to Doxorubicin by the Viscum album Extract.Genomics innovation: transforming healthcare, business, and the global economy.The LungPath study: variation in the diagnostic and staging pathway for patients with lung cancer in England.How to Study Chronic Diseases-Implications of the Convention on the Rights of Persons with Disabilities for Research Designs.Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer.New challenges to psycho-oncology research: Precision medicine oncology and targeted therapies.Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.Communication of cancer-related genetic and genomic information: A landscape analysis of reviews.The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?Opportunities and Challenges in Precision Medicine: Improving Cancer Prevention and Treatment for Asian Americans.The Obesity Paradox in Cancer-Moving Beyond BMI.Parenclitic networks for predicting ovarian cancer.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.Application of n-of-1 treatment trials in schizophrenia: systematic review
P2860
Q26764746-3143E35E-01E4-4A52-8FC5-C0CBBB233EACQ34659468-E709F4A3-D43D-4CD0-93C1-F2081DC97001Q35571891-D6B8DA20-B9F5-4B1B-991C-F13A80658897Q35810608-CECDE670-9205-4105-B2BB-99E1DF0E0095Q36008395-44B86FDA-76A1-4908-9E5C-80D449BEE049Q36299021-74FB46BA-FB1F-471C-BAF1-438B6929C3B1Q36443572-996E7E10-8E10-43A9-B00B-9CABC9E268C5Q37023903-C8749CFD-99E1-4752-8D07-07B7A6E8A4A2Q38358175-694A9BD8-207A-441F-91FA-947AD7DA0EC1Q38375045-757A5F0E-6154-477B-9CF6-855C58461B87Q38383838-A56634ED-5CBA-48E8-A250-515BFE9B0E67Q38603815-8F5CEF90-91E3-499D-98B5-5FEFE99331FFQ38620198-D08DD728-2698-4FF0-8884-03C0AC4DC014Q38814901-F1562FD0-9E3F-45E3-8FF4-A30EEDBFBC79Q38947246-948A7560-D522-48F7-B6C4-9944E891BB35Q39044222-6BB67382-5450-4FB9-9FCB-95E2EBE8F6C8Q40182949-C5EE88C8-2620-41B4-A5A6-39B5034E76B6Q41076261-30D42A93-980B-4E79-A29F-03BD9A9FF683Q41582790-22FAE93D-A035-4210-97E6-58EDE5DAD920Q41913633-97E9D43D-84AF-45B3-8BC9-161FD37EC4E0Q42479250-40DC70E7-A1E3-4F64-82CB-656B5FEE9F86Q47147401-907BE53D-0C62-4F69-B284-F809583BA358Q47987953-9C1C7E0E-0EB0-401A-A6E8-0182811E9CB3Q48021721-5DB5EE6E-945C-4374-A6BB-D5114E02153CQ49551487-912DA405-17B7-4DBB-90CE-61EDEC5F51E9Q51460841-02A8F748-3E5A-4283-8DFF-4029FAB6BF70Q53267051-CE4C761B-30C8-4302-A27C-C33B01D4FBCAQ53544385-A73AC942-5D09-4B9D-8FE7-40E3EC519DB4Q53585358-73ADE38F-E7CD-4328-8692-98BACD20C66CQ55317927-C6958021-C190-4737-8609-7DACCF218593Q55508847-E091322A-C488-4AD3-9C59-1C01956A81A0Q57177782-FB7DE024-6478-4EEE-9D7C-A9D87CC1D790
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Personalised cancer medicine
@ast
Personalised cancer medicine
@en
Personalised cancer medicine
@nl
type
label
Personalised cancer medicine
@ast
Personalised cancer medicine
@en
Personalised cancer medicine
@nl
prefLabel
Personalised cancer medicine
@ast
Personalised cancer medicine
@en
Personalised cancer medicine
@nl
P2860
P3181
P356
P1476
Personalised cancer medicine
@en
P2093
John D. Chester
Sarah E. Jackson
P2860
P3181
P356
10.1002/IJC.28940
P407
P577
2015-07-15T00:00:00Z